|
|
Article: Drug development.(diagnosis: MS)
- Article from:
- Paraplegia News
- Article date:
- July 1, 2009
CopyrightCOPYRIGHT 2009 Paralyzed Veterans of America. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Fast Forward, LLC, a wholly-owned subsidiary of the National Multiple Sclerosis Society (NMSS), and EMD Serono, Inc., an affiliate of Merck KGaA (Darmstadt, Germany), have committed $3 million in 2009 to support innovative early-stage projects directed toward developing therapies to prevent, treat, or reverse nervous-system damage in MS.
This was the first Request for Proposals (RFP) issued under the auspices of a multiyear collaboration between Fast Forward and EMD Serono to accelerate innovation and commercial development of MS therapies. Merck KGaA will provide up to $19 million in total funding for the collaboration.
Fast Forward Hill ...
Related newspaper, magazine, and journal articles:
|
|
Article: EMD Serono plans $50m expansion Biotech will add ...
The Boston Globe;
April 16, 2008 ;
700+ words
...Add EMD Serono Inc. to the growing list of drug companies ... research operations and have space to grow. EMD Serono said it also hopes to hire 100 more researchers ... SA , the Swiss company that includes EMD Serono. Schnee said the company considered ...
|
|